IRES/subdominant epitope inhibitors therapy(MERLIN Biotech)

N/A

Report date: 2024/03/04 17:43:42

Base Information

Drug NameIRES/subdominant epitope inhibitors therapy(MERLIN Biotech)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMerlin Biotech LLC
China Registration ClassN/A

Develop Information

Active CompaniesMerlin Biotech LLC
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A